Sign Up
Stories
Allogene Therapeutics Restates Financial Statements
Share
Advancements in Cancer Treatment and Mar...
Advancements in Lymphoma Treatments
Affini-T Therapeutics at J.P. Morgan Hea...
AB-2100 Phase 1/2 Trial Initiated
Anocca Appoints Martin Welschof to Board...
Atara Biotherapeutics at Health Care Con...
Overview
API
Allogene Therapeutics to restate financial statements due to non-cash accounting adjustments, with no impact on cash and business operations. The company is reiterating its guidance and plans to file amended financial statements soon.
Ask a question
How does the restatement of financial statements reflect the company's overall financial stability and growth prospects?
How might non-cash accounting adjustments impact the reputation and investor confidence in Allogene Therapeutics?
What strategies could Allogene Therapeutics employ to mitigate risks and uncertainties related to product development and regulatory approval?
Article Frequency
0.2
0.4
0.6
0.8
1.0
Nov 2023
Dec 2023
Jan 2024
Coverage
globe